

CORRIGENDUM

In the article by B.M. Piraccini et al.¹, there is an error in the subsection entitled “Safety assessment” on page 291.

The incorrect sentence reads:

Withdrawal rates due to treatment-related TEAEs were 2.8% and 2.2% in the topical finasteride and placebo groups, respectively, and 7.1% in the **topical finasteride group**.

The correct sentence should read:

Withdrawal rates due to treatment-related TEAEs were 2.8% and 2.2% in the topical finasteride and placebo groups, respectively, and 7.1% in the **oral finasteride group**.

REFERENCE

1. Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. *J Eur Acad Dermatol Venereol.* 2022;36:286–94. <https://doi.org/10.1111/jdv.17738>